Alexion Pharmaceuticals (ALXN) PT Lowered to $153.00

Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price decreased by Leerink Swann from $166.00 to $153.00 in a research report report published on Friday. Leerink Swann currently has an outperform rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. Evercore ISI raised shares of Alexion Pharmaceuticals from an in-line rating to an outperform rating in a report on Monday, February 5th. Citigroup lowered their price target on Alexion Pharmaceuticals from $173.00 to $170.00 and set a buy rating for the company in a research report on Friday. Deutsche Bank set a $161.00 price target on Alexion Pharmaceuticals and gave the stock a buy rating in a research report on Friday. Piper Jaffray Companies restated an overweight rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Finally, BidaskClub downgraded Alexion Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $152.77.

Alexion Pharmaceuticals (NASDAQ ALXN) opened at $115.43 on Friday. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The firm has a market cap of $25,790.00, a price-to-earnings ratio of 58.59, a P/E/G ratio of 0.95 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same period last year, the firm posted $1.26 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 9.5% compared to the same quarter last year. research analysts predict that Alexion Pharmaceuticals will post 6.25 EPS for the current year.

In related news, SVP Heidi L. Wagner sold 1,774 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $206,333.94. Following the completion of the sale, the senior vice president now directly owns 47,212 shares in the company, valued at $5,491,227.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,930 shares of company stock valued at $3,378,199. Corporate insiders own 4.35% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ALXN. Dimensional Fund Advisors LP raised its holdings in shares of Alexion Pharmaceuticals by 13.3% in the second quarter. Dimensional Fund Advisors LP now owns 364,268 shares of the biopharmaceutical company’s stock valued at $44,323,000 after acquiring an additional 42,809 shares in the last quarter. AHL Partners LLP bought a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $2,187,000. Macquarie Group Ltd. raised its holdings in shares of Alexion Pharmaceuticals by 76.1% in the second quarter. Macquarie Group Ltd. now owns 131,994 shares of the biopharmaceutical company’s stock valued at $16,060,000 after acquiring an additional 57,026 shares in the last quarter. Gotham Asset Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 35.3% in the second quarter. Gotham Asset Management LLC now owns 29,020 shares of the biopharmaceutical company’s stock valued at $3,531,000 after acquiring an additional 7,570 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Alexion Pharmaceuticals by 49.2% in the second quarter. Cubist Systematic Strategies LLC now owns 10,062 shares of the biopharmaceutical company’s stock valued at $1,224,000 after acquiring an additional 3,316 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals (ALXN) PT Lowered to $153.00” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.com-unik.info/2018/02/13/alexion-pharmaceuticals-alxn-pt-lowered-to-153-00.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit